SARS-CoV-2 spike antibody levels in lung transplantation recipients versus the spectrum in non-immunocompromised persons
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Impaired Humoral Response to Third Dose of BNT162b2 mRNA COVID-19 Vaccine Despite Detectable Spike Protein–specific T cells in Lung Transplant RecipientsTransplantation, 2021
- Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant RecipientsNew England Journal of Medicine, 2021
- Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant RecipientsNew England Journal of Medicine, 2021
- Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipientsThe Journal of Heart and Lung Transplantation, 2021
- Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipientsClinical Research in Cardiology, 2021
- Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody ResponsesACS Nano, 2021
- Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccineThe Lancet Respiratory Medicine, 2021
- Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant RecipientsJAMA, 2021
- Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant RecipientsJAMA, 2021
- Noninvasive monitoring of infection and rejection after lung transplantationProceedings of the National Academy of Sciences, 2015